Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 3—March 2002
Synopsis

Human Campylobacteriosis in Developing Countries1

Akitoye O. Coker*Comments to Author , Raphael D. Isokpehi*, Bolaji N. Thomas*, Kehinde O. Amisu*, and C. Larry Obi†
Author affiliations: *University of Lagos, Idi-Araba, Lagos, Nigeria; †University of Venda for Science and Technology, Thohoyandon, South Africa;

Cite This Article

Abstract

Campylobacteriosis is a collective description for infectious diseases caused by members of the bacterial genus Campylobacter. The only form of campylobacteriosis of major public health importance is Campylobacter enteritis due to C. jejuni and C. coli. Research and control efforts on the disease have been conducted more often in developed countries than developing countries. However, because of the increasing incidence, expanding spectrum of infections, potential of HIV-related deaths due to Campylobacter, and the availability of the complete genome sequence of C. jejuni NCTC 11168, interest in campylobacteriosis research and control in developing countries is growing. We present the distinguishing epidemiologic and clinical features of Campylobacter enteritis in developing countries relative to developed countries. National surveillance programs and international collaborations are needed to address the substantial gaps in the knowledge about the epidemiology of campylobacteriosis in developing countries.

Campylobacteriosis is a collective description for infectious diseases caused by members of the bacterial genus Campylobacter. The only form of campylobacteriosis of major public health importance is Campylobacter enteritis due to C. jejuni and C. coli (1). The rate of Campylobacter infections worldwide has been increasing, with the number of cases often exceeding those of salmonellosis and shigellosis (2). This increase, as well as the expanding spectrum of diseases caused by the organisms, necessitates a clearer understanding of the epidemiology and control of campylobacteriosis.

Surveillance and control of diseases of public health importance in developing countries have focused on diseases such as malaria, tuberculosis, trypanosomiasis, onchocerciasis, and schistosomiasis (3). Programs for diarrhea and acute respiratory illness also exist (4). These programs have extensive support from the World Health Organization (WHO).

Campylobacter is one of the most frequently isolated bacteria from stools of infants with diarrhea in developing countries—a result of contaminated food or water (5,6). However, national surveillance programs for campylobacteriosis generally do not exist in most developing countries despite the substantial burden of disease. Most data available on campylobacteriosis in developing countries were collected as a result of support provided by WHO to many laboratories in developing countries, including grants for epidemiologic studies and Lior serotyping antisera provided by the Public Health Service of Canada (5,7). The number of reviews and updates on human campylobacteriosis in developed countries (811) is greater than that for developing countries (5,6). This disparity may be because Campylobacter-associated diarrhea in developing countries is not pathogenic in patients >6 months of age. However, a community-based longitudinal study provided evidence that infection could be pathogenic beyond the first 6 months of life in developing countries (12). Furthermore, the sequencing and publication of the complete genome of C. jejuni NCTC 11168 have heralded a renaissance of interest in this organism, offering researchers worldwide, including in developing countries, novel ways to contribute to the understanding the organism’s biology (13). Thus, to promote research and control of campylobacteriosis in developing countries, review information on human campylobacteriosis in these countries is urgently needed. We present the distinguishing features of campylobacteriosis in developing countries relative to developed countries.

Incidence

Generally, developing countries do not have national surveillance programs for campylobacteriosis; therefore, incidence values in terms of number of cases for a population do not exist. Availability of national surveillance programs in developed countries has facilitated monitoring of sporadic cases as well as outbreaks of human campylobacteriosis (2,811). Most estimates of incidence in developing countries are from laboratory-based surveillance of pathogens responsible for diarrhea. Campylobacter isolation rates in developing countries range from 5 to 20% (6). Table 1 shows isolation rates for some countries according to WHO regions from studies of diarrhea in children <5 years old (1425). Despite the lack of incidence data from national surveys, case-control community-based studies have provided estimates of 40,000 to 60,000/100,000 for children <5 years of age (6,12). In contrast, the figure for developed countries is 300/100,000 (8). Estimates in the general population in developing and developed countries are similar, approximately 90/100,000 (5,6,8), confirming the observation that campylobacteriosis is often a pediatric disease in developing countries. The isolation and incidence rates in some developing countries have increased since their initial reports (17). This increase has often been attributed to improved diagnostic methods, but an actual increase in incidence was observed in Campylobacter-associated diarrhea in the Caribbean island of Curaçao (26).

Age of Infection

In developing countries, Campylobacter is the most commonly isolated bacterial pathogen from <2-year-old children with diarrhea (Table 2). The disease does not appear to be important in adults. In contrast, infection occurs in adults and children in developed countries. Poor hygiene and sanitation and the close proximity to animals in developing countries all contribute to easy and frequent acquisition of any enteric pathogen, including Campylobacter. Although infections in infants appear to decline with age (Table 2), a comprehensive community-based cohort study in Egypt has shown that infection could be pathogenic regardless the age of the child, underscoring the need for strengthening prevention and control strategies for campylobacteriosis (12).

Polymicrobial Infections Involving Campylobacter

Campylobacter is isolated relatively frequently with another enteric pathogen in patients with diarrhea in developing countries. In some cases half or more patients with Campylobacter enteritis also had other enteric pathogens (23,30). Organisms reported include Escherichia coli, Salmonella, Shigella, Giardia lamblia, and Rotavirus. Polymicrobial infections involving Campylobacter are rare in developed countries (5,6).

Isolation of Campylobacter in Healthy Children

The recovery of Campylobacter organisms from children without diarrhea is common in developing countries. In some reports the isolation rates for symptomatic and asymptomatic children were not statistically significant. Values as high as 14.9% in controls have been observed (14). Acquisition of the pathogen because of poor sanitation and contact with animals early in life may explain the isolation from healthy children. Campylobacter is not frequently recovered from asymptomatic persons in developed countries, as observed in the Netherlands, where a 0.5% isolation rate has been reported (9).

Seasonal Variation

In developing countries, Campylobacter enteritis has no seasonal preference; in contrast, in developed countries epidemics occur in summer and autumn (2). Isolation peaks vary from one country to another and also within countries (12,31,32). The lack of seasonal preference may be due to lack of extreme temperature variation as well as lack of adequate surveillance for epidemics (5,6).

Distribution of Campylobacter Species

C. jejuni and C. coli are the two main species isolated in developing countries. The isolation rate of C. jejuni exceeds that of C. coli, similar to observations in most developed countries (8,9). Lior biotyping and serotyping methods have been used in developing countries to subtype strains of C. jejuni and C. coli (5,6). Table 3 shows the distribution of the subtypes from three African countries. Biotype I was the most common, followed by biotype II. The prevalence of specific serotypes only in symptomatic children may indicate virulence traits or treatment, in cases of gastroenteritis (33). Furthermore, correlation between biotypes and serotypes isolated from humans and animals indicates that campylobacteriosis is zoonotic (36). Penner serotyping scheme and DNA-based typing, extensively used in developed countries, have been proposed for use in developing countries (37).

Species other than C.jejuni and C. coli—such as C. upsaliensis, C. concisus, and aerotolerant campylobacters (Arcobacter)—may also be of pathogenic importance; however, diagnostic capacities to determine their distribution are lacking in developing countries (38). These other Campylobacter species constitute over 50% of campylobacters isolated at the Red Cross Children’s Hospital, Cape Town, South Africa, for example. (A method termed the Cape Town Protocol is used to isolate Campylobacter species at this facility [39]). This higher incidence is also supported by a 16% isolation rate of Arcobacter species in a 4-month survey from poultry drainage water in Lagos, Nigeria (40).

Antibiotic Resistance in Campylobacter Isolates

Campylobacter enteritis is a self-limiting disease, and antimicrobial therapy is not generally recommended. However, antimicrobial agents are recommended for extraintestinal infections and for treating immunocompromised persons. Erythromycin and ciprofloxacin are drugs of choice (10). The rate of resistance to these drugs is increasing in both developed and developing countries, although the incidence is higher in developing countries. Use of these drugs for infections other than gastroenteritis and self-medication are often the causes of resistance in developing countries; in developed countries, resistance is due to their use in food animals and travel to developing countries. The increase in erythromycin resistance in developed countries is often low and stable at approximately 1% to 2%; this is not true for developing countries (41,42). For example, in 1984, 82% of Campylobacter strains from Lagos, Nigeria, were sensitive to erythromycin; 10 years later, only 20.8% were sensitive (17). In addition, resistance to another macrolide, azithromycin, was found in 7% to 15% of Campylobacter isolates in 1994 and 1995 in Thailand (43). The increasing rate of resistance to the fluoroquinolone, ciprofloxacin limits its clinical usefulness. In Thailand, ciprofloxacin resistance among Campylobacter species increased from zero before 1991 to 84% in 1995 (43). Recent data have shown a marked increase in resistance to quinolones in developed countries (41,42,4446) (Table 4).

Campylobacter as a Cause of Travelers’ Diarrhea

Travel to a developing country is a risk factor for acquiring Campylobacter-associated diarrhea. The diarrhea is more severe, and strains are associated with antibiotic resistance (47,48). Furthermore, campylobacteriosis acquired abroad contribute to the number of cases reported in developed countries (49). Among Finnish tourists visiting Morocco, the disease was more prevalent in winter months (50).

Clinical Features

The clinical spectrum of Campylobacter enteritis ranges from a watery, nonbloody, noninflammatory diarrhea to a severe inflammatory diarrhea with abdominal pain and fever. Disease is less severe in developing countries than in developed countries (5,6). In developed countries, disease is characterized by bloody stool, fever, and abdominal pain that is often more severe than that observed for Shigella and Salmonella infections. In developing countries the features reported are watery stool, fever, abdominal pain, vomiting, dehydration, and presence of fecal leukocytes; patients are also often underweight and malnourished (12,31,51). In Lagos, Nigeria, Campylobacter enteritis is characterized by a history of watery offensive-smelling stool lasting <5 days (51).

Guillain-Barré Syndrome

Guillain-Barré Syndrome (GBS) is an autoimmune disorder of the peripheral nervous system, which is characterized by acute flaccid paralysis. C. jejuni infection is the most frequently identified infection preceding GBS (52). In the developing world, sporadic GBS cases associated with C. jejuni infection have been reported from Curaçao, China, India, and South Africa (26,5355). A comparative study between Curaçao and southwest Netherlands indicated that disease in Curaçao was more severe, had a higher incidence of preceding gastroenteritis, and had greater seasonal fluctuation (26). Serotype O:19 is most prevalent worldwide, although other serotypes, such as O:1, O:2, O:57, O:16, O:23, O:37, O:41, and O:44, have been reported (52). C. jejuni strain O:41 appears to be restricted to Cape Town, South Africa, and represents a genetically stable clone (55,56). Detailed studies of the role of GBS in acute flaccid paralysis in developing countries, especially in polio-endemic areas, are needed.

Campylobacter Infection in the Setting of HIV

Campylobacter-associated diarrhea and bacteremia occur in HIV/AIDS patients worldwide. The species isolated include C. jejuni, C. coli, C. upsaliensis, Arcobacter butzleri, Helicobacter fennelliae, and H. cinaedii (57,58). The incidence of clinical manifestations is higher than in HIV-negative patients, with substantial mortality and morbidity. Furthermore, antibiotic resistance and recurrent infections have been observed (59). The incidence of HIV/AIDS is higher in developing countries than in developed countries and contributes substantially to deaths among <5-year-old children in epidemic settings (60). Thus, infants in developing countries are at risk of impaired immunity to Campylobacter enteritis. In addition, HIV/AIDS can increase the number of cases of campylobacteriosis in the adult population in these countries. These observations further support the need for improved understanding of the epidemiology of campylobacteriosis in developing countries.

Immunologic Aspects

In developing countries, such as Bangladesh, Thailand, Central African Republic, and Mexico, healthy children and adults are constantly exposed to Campylobacter antigens in the environment. As a consequence, serum antibodies to Campylobacter species develop very early in life in children in developing countries, and the levels of such antibodies tend to be much higher than those in children in the developed world such as in the United States (6164). In Nigeria, children who had diarrhea and children who were healthy both had antibodies in their sera that could agglutinate C. jejuni; the difference in antibody responses between these groups of children was not statistically significant (65). Thus, antibody responses alone should be interpreted with caution in diagnosing Campylobacter infections.

In spite of shortcomings in the use of antibodies for diagnosis, increase in the level of anti-flagellar antibody had an inverse correlation with the rates of Campylobacter enteritis in the Central African Republic (63). An age-related relationship in the development of immunity to Campylobacter antigens has also been suggested to account for the age-related declines in the case-to-infection ratio and the period of excretion during the convalescent phase (28,66).

Usually, as age increases, level of antibody tends to increase. At the earliest stages in life (first 6 months), immunoglobulin (Ig) A, IgG, and IgM levels in response to Campylobacter infection are minimal, but thereafter increases are observed in response to infection. The poor serologic response during the first 6 months of life may be due either to a primary response to Campylobacter or to the presence of maternal antibodies via the placenta or breast milk.

Breast-feeding has been reported to play a role in C. jejuni-induced diarrhea. It decreases the number of episodes and the duration of diarrhea (67). In Algeria, exclusively breast-fed infants had fewer symptomatic Campylobacter infections than infants who were both breast-fed and bottle-fed (14).

Results of experimental observations among Mexican children have also shown that immunity to Campylobacter after primary infection may prevent bloody diarrhea from developing and subsequently prevent any disease from manifesting (68). In the developed world, the epidemiology may be different because most cases are usually primary infections with more severe clinical manifestations, greater numbers of people with bloody diarrhea (50%, as opposed to 15% in developing countries), and a more prolonged duration of excretion (approximately 15 days, compared with 7 days in developing countries) (28). The widespread immunity seen among adults in developing countries is absent in adults in developed countries (64).

Sources of Human Campylobacteriosis

Campylobacter infection is hyperendemic in developing countries. The major sources of human infections are environmental contamination and foods. Human-to-human transmission as a result of prolonged convalescent-phase excretion and high population density have also been suggested (5,12), although observations from developed countries show these are less likely factors (2).

Environmental Contamination

Wild birds as well as domestic and companion animals are known reservoirs for Campylobacter species, and shedding of the bacteria from them causes contamination of the environment. C. jejuni and C. coli have been isolated from chickens, goats, sheep, and pigs in developing countries (69,70). Strains isolated from human and chickens were phenotypically and genotypically correlated, confirming that chickens are an important source of human campylobacteriosis in developing countries (36). Poultry is also an important source of campylobacteriosis in developed countries. Extensive epidemiologic investigations have been done in those countries to identify sources of contamination and routes of transmission to humans to facilitate control efforts (71). Risk factors for acquiring campylobacters in developing countries include presence of an animal in the cooking area, uncovered garbage in cooking areas, and lack of piped water (12).

Foods

Campylobacter-contaminated foods—the result of poor sanitation—are an important potential source of infection in humans. For example, campylobacters were isolated from 40% and 77% of retail poultry meat sold in Bangkok, Thailand, and Nairobi, Kenya, respectively (72,73). The serotypes of the organisms isolated in Thailand were similar to those of organisms isolated from humans. In Mexico City, a survey of ready-to-eat roasted chickens showed that they were contaminated with campylobacters (74). In developed countries, risk factors associated with foods include occupational exposure to farm animals, consumption of raw milk or milk products, and unhygienic food preparation practices (2).

Estimates of Impact of Human Campylobacteriosis in Developing Countries

The Disability Adjusted Life Year (DALY) is the basic unit used in Burden of Disease (BoD) methodology to quantify the impact of disease on a population (75). DALYs have been applied in the Dutch population to measure the mean health burden of Campylobacter-associated illness in the period 1990–1995 (76). The mean estimate was 1,400 DALYs per year; the main determinants of health burden were acute gastroenteritis (440 DALYs), gastroenteritis-related mortality (310 DALYs), and residual symptoms of GBS (340 DALYs). Although data on DALYs due to campylobacteriosis in developing countries are not available, diarrhea, which is a clinical manifestation of campylobacteriosis, was one of the top three causes of death and disease in developing countries in 1990 (75). The disease is projected globally to remain one of the top 10 by 2020. (The burden of campylobacteriosis in developing countries may increase by 2020 because HIV is projected to move up to the 10th position from 28th by 2020.) Considering the higher incidence of campylobacteriosis in developing countries, DALYs for the disease in developing countries will likely be higher than those of the Dutch population.

Conclusions

The incidence of human campylobacteriosis is increasing worldwide and has attracted the attention of WHO (http://www1.oecd.org/agr/prog/sum-copenhagen00.htm). Ssubstantial gaps in knowledge about the epidemiology of campylobacteriosis in developing countries still exist. Present reported estimates of incidence are based on isolation rates from laboratory- and community-based studies conducted from 1980 to 1995. When various socioeconomic and health changes in developing countries are taken into account, these values may have changed considerably. Thus, public health awareness about the problem is needed, as are strengthened diagnostic facilities for campylobacteriosis, with a view towards setting up national surveillance programs. Such programs would determine the incidence rates, epidemiologic risk factors, interaction of HIV/AIDS and campylobacteriosis, seasonal variation, current state of resistance to antimicrobial agents, role of species other than C. jejuni and C. coli, and the role of campylobacteriosis in GBS. Collaboration among researchers in developed and developing countries needs to be strengthened, leading to development of regional centers of excellence. Funding organizations should provide incentives for North-South collaborations in Campylobacter research, as is done in other diseases such as malaria and trypanosomiasis that are endemic in some developing countries. All these should contribute to understanding of the global epidemiology of human campylobacteriosis.

Akitoye O. Coker is a Consultant Microbiologist and Professor of Medical Microbiology at the University of Lagos, Nigeria. He pioneered research into Campylobacter enteritis in Lagos, Nigeria.

Top

Acknowledgment

We thank Henrik C. Wegener and Klaus Stoehrk for their useful suggestions during the preparation of this manuscript.

Top

References

  1. Nachamkin  I, Blaser  MJ. Campylobacter, 2nd edition. Washington: American Society for Microbiology; 2000.
  2. Altekruse  SF, Stern  NJ, Fields  PI, Swerdlow  DL. Campylobacter jejuni--an emerging foodborne pathogen. Emerg Infect Dis. 1999;5:2835.PubMedGoogle Scholar
  3. Tropical disease research: progress 1999-2000. Fifteenth Programme report of the UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases. (TDR/GEN/01.5). Geneva: World Health Organization; 2001.
  4. Lambrechts  T, Bryce  J, Orinda  V. Integrated management of childhood illness: a summary of first experiences. Bull World Health Organ. 1999;77:58294.PubMedGoogle Scholar
  5. Taylor  DN. Campylobacter infections in developing countries. In: Nachamkin I, Blaser MJ, Tompkins LS, editors. Campylobacter jejuni: Current status and future trends. Washington: American Society for Microbiology; 1992. p.20-30.
  6. Oberhelman  RA, Taylor  DN. Campylobacter infections in developing countries. In: Nachamkin I, Blaser MJ, editors. Campylobacter, 2nd edition. Washington: American Society for Microbiology; 2000. p.139-53.
  7. Coker  AO, Isokpehi  RD, Thomas  BN, Amisu  KO. International collaboration on campylobacters: Experience from Lagos, Nigeria. [Abstract S-05]. In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):168.
  8. Tauxe  RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, Tompkins LS, editors. Campylobacter jejuni: Current and future trends. Washington: American Society for Microbiology; 1992. p.9-12.
  9. de Wit  MAS, Koopmans  MPG, Kortbeek  LM, van Leeuwen  NJ, Bartelds  AIM, van Duynhoven  YTHP. Gastroenteritis in sentinel general practices, the Netherlands. Emerg Infect Dis. 2001;7:8291.PubMedGoogle Scholar
  10. Engberg  J, Aarestrup  FM, Taylor  DE, Gerner-Smidt  P, Nachamkin  I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance and trends in human isolates. Emerg Infect Dis. 2001;7:2434.PubMedGoogle Scholar
  11. Frost  JA. Current epidemiological issues in human campylobacteriosis. J Appl Microbiol. 2001;90(Suppl):85S95S. DOIGoogle Scholar
  12. Rao  MR, Naficy  AB, Savarino  SJ, Abu-Elyazeed  R, Wierzba  TF, Peruski  LF, Pathogenicity and convalescent excretion of Campylobacter in rural Egyptian children. Am J Epidemiol. 2001;154:16673. DOIPubMedGoogle Scholar
  13. Wren  BW, Linton  D, Dorrell  N, Karlyshev  AV. Post genome analysis of Campylobacter jejuni. J Appl Microbiol. 2001;90(Suppl):36S44S. DOIGoogle Scholar
  14. Megraud  F, Boudraa  G, Bessaoud  K, Bensid  S, Dabis  F, Soltana  R, Incidence of Campylobacter infection in infants in western Algeria and the possible protective role of breast feeding. Epidemiol Infect. 1990;105:738.PubMedGoogle Scholar
  15. Koulla-Shiro  S, Loe  C, Ekoe  T. Prevalence of Campylobacter enteritis in children from Yaounde (Cameroon). Cent Afr J Med. 1995;41:914.PubMedGoogle Scholar
  16. Gedlu  E, Aseffa  A. Campylobacter enteritis among children in north-west Ethiopia: a 1-year prospective study. Ann Trop Paediatr. 1996;16:20712.PubMedGoogle Scholar
  17. Coker  AO, Adefeso  AO. The changing patterns of Campylobacter jejuni/coli in Lagos, Nigeria after ten years. East Afr Med J. 1994;71:43740.PubMedGoogle Scholar
  18. Lindblom  GB, Ahren  C, Changalucha  J, Gabone  R, Kaijser  B, Nilsson  LA, Campylobacter jejuni/coli and enterotoxigenic Escherichia coli (ETEC) in faeces from children and adults in Tanzania. Scand J Infect Dis. 1995;27:58993. DOIPubMedGoogle Scholar
  19. Simango  C, Nyahanana  M. Campylobacter enteritis in children in an urban community. Cent Afr Med J. 1997;43:1725.
  20. Mangia  AH, Duarte  AN, Duarte  R, Silva  LA, Bravo  VL, Leal  MC. Aetiology of acute diarrhoea in hospitalized children in Rio de Janeiro City, Brazil. J Trop Pediatr. 1993;39:3657.PubMedGoogle Scholar
  21. Ramiro Cruz  J, Cano  F, Bartlett  AV, Mendez  H. Infection, diarrhea, and dysentery caused by Shigella species and Campylobacter jejuni among Guatemalan rural children. Pediatr Infect Dis J. 1994;13:21623.PubMedGoogle Scholar
  22. Na'was  TE, Abo-Shehada  MN. A study of the bacterial and parasitic causes of acute diarrhoea in northern Jordan. J Diarrhoeal Dis Res. 1991;9:3059.PubMedGoogle Scholar
  23. Albert  MJ, Faruque  AS, Faruque  SM, Sack  RB, Mahalanabis  D. Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol. 1999;37:345864.PubMedGoogle Scholar
  24. Echeverria  P, Taylor  DN, Lexsomboon  U, Bhaibulaya  M, Blacklow  NR, Tamura  K, Case-control study of endemic diarrheal disease in Thai children. J Infect Dis. 1989;159:5438.PubMedGoogle Scholar
  25. Yamashiro  T, Nakasone  N, Higa  N, Iwanaga  M, Insisiengmay  S, Phounane  T, Etiological study of diarrheal patients in Vientiane, Lao People's Democratic Republic. J Clin Microbiol. 1998;36:21959.PubMedGoogle Scholar
  26. van Koningsveld  R, Rico  R, Gerstenbluth  I, Schmitz  PI, Ang  CW, Merkies  IS, Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curacao. Neurology. 2001;56:146772.PubMedGoogle Scholar
  27. Desheng  L, Zhixin  C, Bolun  W. Age distribution of diarrhoeal and healthy children infected with Campylobacter jejuni. J Trop Med Hyg. 1992;95:21820.PubMedGoogle Scholar
  28. Taylor  DN, Perlman  DM, Echeverria  PD, Lexomboon  U, Blaser  MJ. Campylobacter immunity and quantitative excretion rates in Thai children. J Infect Dis. 1993;168:7548.PubMedGoogle Scholar
  29. Haq  JA, Rahman  KM. Campylobacter jejuni as a cause of acute diarrhoea in children: a study at an urban hospital in Bangladesh. J Trop Med Hyg. 1991;94:504.PubMedGoogle Scholar
  30. Bichile  LS, Saraswati  K, Popat  UR, Nanivadekar  SA, Deodhar  LP. Acute Campylobacter jejuni enteritis in 385 hospitalised patients. J Assoc Physicians India. 1992;40:1646.PubMedGoogle Scholar
  31. Bhadra  RK, Lior  H, Misra  SK, Pal  SC, Nair  GB. Serotypes & biotypes of Campylobacter jejuni & C. coli from diverse sources in Calcutta. Indian J Med Res. 1989;89:2258.PubMedGoogle Scholar
  32. Nath  G, Shukla  BN, Reddy  DC, Sanyal  SC. A community study on the aetiology of childhood diarrhoea with special reference to Campylobacter jejuni in a semiurban slum of Varanasi, India. J Diarrhoeal Dis Res. 1993;11:1658.PubMedGoogle Scholar
  33. Alabi  SA, Coker  AO, Dosunmu-Ogunbi  O, Odugbemi  T. Biotype and serogroup distribution of Campylobacter isolates from children in Nigeria. J Clin Microbiol. 1986;24:8568.PubMedGoogle Scholar
  34. Georges-Courbot  MC, Gouandjika  I, Martin  PM, Georges  AJ. Biotype and Lior serogroup distribution of enteric Campylobacter isolated from children in Bangui (Central African Republic), and comparison with Penner serotypes. Res Microbiol. 1989;140:48997. DOIPubMedGoogle Scholar
  35. Lastovica  AJ, le Roux  E, Congi  RV, Penner  JL. Distribution of sero-biotypes of Campylobacter jejuni and C. coli isolated from paediatric patients. J Med Microbiol. 1986;21:15.PubMedGoogle Scholar
  36. Adegbola  RA, Alabi  SA, Akinkuade  FO, Coker  AO, Odugbemi  T. Correlation between human and animal bio-serogroups of Campylobacter isolates in Nigeria. J Trop Med Hyg. 1990;93:2803.PubMedGoogle Scholar
  37. Smith  SI, Olukoya  DK, Fox  AJ, Coker  AO. Deoxyribonucleic acid restriction digest patterns in Campylobacter species: a comparison with Penner serotype. Br J Biomed Sci. 2000;57:13741.PubMedGoogle Scholar
  38. Vandenberg  O, Dediste  A, Vlaes  L, Ebraert  A, Retore  P, Douat  N, Prevalence and clinical features of non jejuni/coli Campylobacter species and related organisms in stool specimens. [Abstract P-22]. In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291(Suppl 31):144.
  39. le Roux  E, Lastovica  AJ. The Cape Town Protocol: how to isolate the most campylobacters for your dollar, pound, franc, yen, etc. In: Lastovica AJ, Newell DG, Lastovica EE, editors. Proceedings of the 9th International Workshop on Campylobacter, Helicobacter and Related Organisms, Cape Town, South Africa Sept 15-19 1997. Cape Town: Institute of Child Health; 1998. p. 30-33.
  40. Amisu  KO, Coker  AO, Isokpehi  RD. First isolation of aerotolerant Campylobacter (Arcobacter) strains in Nigeria. [Abstract P-18] In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):143.
  41. Steinbrückner  B, Ruberg  F, Vetter-Knoll  M, Kist  M. Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Freiburg from 1992 to 2000. [Abstract B-12] In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):8.
  42. Feierl  G, Wagner  U, Sixl  B, Grisold  A, Daghofer  E, Marth  E. Epidemiology of campylobacteriosis and development of resistance in Styria, Austria. [Abstract B-15]. In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):9.
  43. Hoge  CW, Gambel  JM, Srijan  A, Pitarangsi  C, Echeverria  P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:3415. DOIPubMedGoogle Scholar
  44. Wickin  HV, Thwaites  RT, Frost  JA. Drug resistance in Campylobacter species in England and Wales, 1993-2001. [Abstract B-05] In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001; 291 (Suppl 31):6.
  45. Nachamkin  I, Ung  H, Li  M. Fluoroquinolone resistant Campylobacter jejuni in Philadelphia, 1982-2000. [Abstract B-06]. In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):6.
  46. Melby  KK, Mannsåker  T. Antibiotic sensitivity pattern of Campylobacter spp recovered over a ten year period from patients residing in Oslo Area. [Abstract B-17]. In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):9.
  47. Gallardo  F, Gascon  J, Ruiz  J, Corachan  M, Jimenez de Anta  M, Vila  J. Campylobacter jejuni as a cause of traveler's diarrhea: clinical features and antimicrobial susceptibility. J Travel Med. 1998;5:236. DOIPubMedGoogle Scholar
  48. Shlim  DR, Hoge  CW, Rajah  R, Scott  RM, Pandy  P, Echeverria  P. Persistent high risk of diarrhea among foreigners in Nepal during the first 2 years of residence. Clin Infect Dis. 1999;29:6136. DOIPubMedGoogle Scholar
  49. Smith  KE, Besser  JM, Hedberg  CW, Leano  FT, Bender  JB, Wicklund  JH, Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med. 1999;340:152532. DOIPubMedGoogle Scholar
  50. Mattila  L, Siitonen  A, Kyronseppa  H, Simula  I, Oksanen  P, Stenvik  M, Seasonal variation in etiology of travelers' diarrhea. Finnish-Moroccan Study Group. J Infect Dis. 1992;165:3858.PubMedGoogle Scholar
  51. Coker  AO, Dosunmu-Ogunbi  O. Gastroenteritis due to Campylobacter jejuni in Lagos, Nigeria. Cent Afr J Med. 1985;31:724.PubMedGoogle Scholar
  52. Nachamkin  I, Allos  BM, Ho  T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 1998;11:55567.PubMedGoogle Scholar
  53. Ho  TW, Mishu  B, Li  CY, Gao  CY, Cornblath  DR, Griffin  JW, Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597605. DOIPubMedGoogle Scholar
  54. Hariharan  H, Naseema  K, Kumaran  C, Shanmugam  J, Nair  MD, Radhakrishnan  K. Detection of Campylobacter jejuni/C. coli infection in patients with Guillain-Barré syndrome by serology and culture. New Microbiol. 1996;19:26771.PubMedGoogle Scholar
  55. Lastovica  AJ, Goddard  EA, Argent  AC. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis. 1997;176(Suppl 2):S13943. DOIPubMedGoogle Scholar
  56. Wassenaar  TM, Fry  BN, Lastovica  AJ, Wagenaar  JA, Coloe  PJ, Duim  B. Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain-Barre syndrome. J Clin Microbiol. 2000;38:8746.PubMedGoogle Scholar
  57. Quinn  TC. Diversity of Campylobacter species and its impact on patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24:11147. DOIPubMedGoogle Scholar
  58. Lastovica  AJ, Mitchie  C, Maartens  G. Campylobacter infection in HIV+ South African children and adults. [Abstract Q-01]. In: Hacker J, editor. Abstracts of scientific presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol 2001;291 (Suppl 31):151.
  59. Germani  Y, Minssart  P, Vohito  M, Yassibanda  S, Glaziou  P, Hocquet  D, Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg. 1998;59:100814.PubMedGoogle Scholar
  60. Adetunji  J. Trends in under-5 mortality rates and the HIV/AIDS epidemic. Bull World Health Organ. 2000;78:12006.PubMedGoogle Scholar
  61. Blaser  MJ, Black  RE, Duncan  DJ, Amer  J. Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol. 1985;21:1647.PubMedGoogle Scholar
  62. Blaser  MJ, Taylor  DN, Echeverria  P. Immune response to Campylobacter jejuni in a rural community in Thailand. J Infect Dis. 1986;153:24954.PubMedGoogle Scholar
  63. Martin  PM, Mathiot  J, Ipero  J, Kirimat  M, Georges  AJ, Georges-Courbot  MC. Immune response to Campylobacter jejuni and Campylobacter coli in a cohort of children from birth to 2 years of age. J Clin Microbiol. 1989;57:25426.
  64. Blaser  MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis. 1997;176(Suppl. 2):S1035. DOIPubMedGoogle Scholar
  65. Obi  CL, Coker  AO. Campylobacter jejuni antibody in patients with diarrhoea and asymptomatic individuals in Lagos, Nigeria. Cent Afr J Med. 1989;66:2769.
  66. Taylor  DN, Echeverria  P, Pitarangsi  C, Seriwatana  J, Bodhidatta  L, Blaser  MJ. Influence of strain characteristics and immunity on the epidemiology of Campylobacter infections in Thailand. J Clin Microbiol. 1988;26:8638.PubMedGoogle Scholar
  67. Ruiz-Palacious  GM, Calva  JJ, Pickering  LK, Lopez-Vidal  Y, Volkow  P, Pezzarossi  H, Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk. J Pediatr. 1990;116:70713. DOIPubMedGoogle Scholar
  68. Calva  JJ, Ruiz-Palacious  GM, Lopez-Vidal  AB, Ramos  A, Bojalil  R. Cohort study of intestinal infection with Campylobacter in Mexican children. Lancet. 1988;I:5036. DOIGoogle Scholar
  69. Coker  AO, Isokpehi  RD, Thomas  BN, Fagbenro-Beyioku  AF, Omilabu  SA. Zoonotic infections in Nigeria: overview from a medical perspective. Acta Trop. 2000;76:5963. DOIPubMedGoogle Scholar
  70. Raji  MA, Adekeye  JO, Kwaga  JK, Bale  JO. Bioserogroups of Campylobacter species isolated from sheep in Kaduna State, Nigeria. Small Rumin Res. 2000;37:21521. DOIPubMedGoogle Scholar
  71. Pattison  M. Practical intervention strategies for Campylobacter. J Appl Microbiol. 2001;90(Suppl):121S5S. DOIGoogle Scholar
  72. Rasrinaul  L, Suthienkul  O, Echeverria  PD, Taylor  DN, Seriwatana  J, Bangtrakulnonth  A, Foods as a source of enteropathogens causing childhood diarrhea in Thailand. Am J Trop Med Hyg. 1988;39:97102.PubMedGoogle Scholar
  73. Osano  O, Arimi  SM. Retail poultry and beef as sources of Campylobacter jejuni. East Afr Med J. 1999;76:1413.PubMedGoogle Scholar
  74. Quinones-Ramirez  EI, Vazquez-Salinas  C, Rodas-Suarez  OR, Ramos-Flores  MO, Rodriguez-Montano  R. Frequency of isolation of Campylobacter from roasted chicken samples from Mexico City. J Food Prot. 2000;63:1179.PubMedGoogle Scholar
  75. Murray  CJL, Lopez  AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. (Global Burden of Disease and Injury Series, Vol. I). Cambridge (MA): Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.
  76. Havelaar  AH, de Wit  MA, van Koningsveld  R, van Kempen  E. Health burden in the Netherlands due to infection with thermophilic Campylobacter spp. Epidemiol Infect. 2000;125:50522. DOIPubMedGoogle Scholar

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid0803.010233

1 Portions of this review were presented at the World Health Organization Consultation on the Increasing Incidence of Campylobacteriosis in Humans, Copenhagen, Denmark, November 1-25, 2000. In addition, relevant emerging information from the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, held in Freiburg, Germany, September 1-5, 2001, are included.

Table of Contents – Volume 8, Number 3—March 2002

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Akitoye O. Coker, Campylobacteria Research Laboratory, Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; fax: 234-1-5851432;

Send To

10000 character(s) remaining.

Top

Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external